Relievant Medsystems said yesterday that it plans to move to Minnesota now that it’s closed on a $58 million Series E round. Led by Endeavour Vision, joined by new backer RK Mellon and existing investors New Enterprise Assoc., Canaan Ventures, Morgenthaler and Emergent Ventures, the round is earmarked for U.S. commercialization of Relievant’s Intracept intraosseous nerve […]
Relievant Medsystems today released the results from the Smart trial of its Intracept intraosseous nerve ablation system exploring its usefulness at treating chronic lower back pain, touting significant decreases in pain from baseline at three months. The Intracept system is designed to use radio frequency energy delivered through specially designed instruments during a minimally invasive surgical […]
Relievant Medsystems said it named former Cameron Medical chief Kevin Hykes to be its new CEO, effective immediately. Hykes, who led Cameron Health to a $1.35 billion buyout in 2012 by Boston Scientific (NYSE:BSX), replaced Alex DiNello, who was named COO, Relievant said. Relievant makes the Intracept device for treating lower back pain. Hykes was most recently […]
Relievant Medsystems said today that it raised a $36 million equity round to support clinical trials for its Intracept intraosseous nerve ablation system. The Intracept system is designed to use radio frequency energy delivered through specially designed instruments during a minimally invasive surgical procedure to access and ablate the basivertebral nerve. The company touts the system as […]
Relievant Medsystems said today it won FDA 510(k) clearance for its Intracept intraosseous nerve ablation system designed for the treatment of chronic lower back pain. The company touted the system as the 1st specific therapy to relieve chronic lower back pain which has persisted for at least 6 months and not responded to conservative care […]
Relievant Medsystems won FDA investigational device exemption for its Intracept back pain therapy, paving the way for the medical device company to continue its SMART pivotal clinical trial.
The Redwood City, Calif.-based company said it will expand the 200-patient randomized, controlled trial to 20 sites across the U.S., where it will evaluate the Intracept therapy in treatment of chronic low back pain.
Charles River Laboratories International Inc. (NYSE:CRL) announced this week that its research models and preclinical services, hand in hand with shuffling its executive deck to drive growth.
Cancer diagnostics firm Neoprobe Corp. (NYSE Amex:NEOP) pressed past the controversy surrounding its Lymphoseek radiopharmaceutical and submitted a new drug application for FDA review.
The Dublin, Ohio-based company hopes to win clearance for Lymphoseek for use in intraoperative lymphatic mapping, a surgical procedure that identifies and biopsies lymph nodes for traces of cancer.